Urothelial Carcinoma Bladder Clinical Trial
Official title:
Bladder Sparing Treatment of Tislelizumab Combined With Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer (T2-3N0M0): a Phase II Prospective Study
This is a phase II open label single-arm prospective study aiming to investigate the efficacy of PD-1 inhibitor Tislelizumab combined with conventional gemcitabine and cisplatin as bladder sparing treatment for patients with PD-L1 positive muscle invasive bladder carcinoma (T2-3N0M0).
The study will enroll 20 patients with adequate organ function and performance status who either wish to attempt bladder preserving therapy or are ineligible for radical cystectomy. The bladder samples must be available and assessed as positive for PD-L1 expression . Patients will receive transurethral resection or partial cystectomy to remove all visible tumors with no residual disease left. After the surgery, patients will receive 8 cycles of tislelizumab combined with 4-6 cycles of gemcitabine and cisplatin. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03606174 -
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05839119 -
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
|
Phase 1 | |
| Completed |
NCT03558503 -
A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
|
Phase 2 | |
| Completed |
NCT05136898 -
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)
|
Phase 3 | |
| Not yet recruiting |
NCT06184516 -
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
|
Phase 2 | |
| Withdrawn |
NCT06090318 -
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03185468 -
Intervention of Bladder Cancer by CAR-T
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05243550 -
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
|
Phase 3 | |
| Recruiting |
NCT05312671 -
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT02951325 -
Bladder Cancer Adjuvant Radiotherapy Trial
|
N/A | |
| Recruiting |
NCT05375903 -
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
|
Phase 1 | |
| Active, not recruiting |
NCT04386746 -
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05656235 -
Renal Retention in High Grade Upper Tract Urothelial Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06331299 -
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT05037279 -
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
|
Phase 3 | |
| Terminated |
NCT04688931 -
A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
|
Phase 3 | |
| Recruiting |
NCT05241340 -
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT05077709 -
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
|
Phase 2 | |
| Completed |
NCT04200963 -
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04770974 -
Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic
|